NCT00098670View on ClinicalTrials.gov

Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
B-cell Chronic Lymphocytic LeukemiaStage I Chronic Lymphocytic LeukemiaStage II Chronic Lymphocytic LeukemiaStage III Chronic Lymphocytic LeukemiaStage IV Chronic Lymphocytic Leukemia
Interventions
BIOLOGICAL

alemtuzumab

Given SC

BIOLOGICAL

rituximab

Given IV

DRUG

fludarabine phosphate

Given IV

Trial Locations (2)

43210

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus

60606

Cancer and Leukemia Group B, Chicago

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00098670 - Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter